1. Stoke Therapeutics leads in RNA medicine for Dravet syndrome. 2. Zorevunersen is a promising disease-modifying treatment in Phase 3 study. 3. CEO Ian F. Smith will present at key investor conferences in September. 4. Investors can access live webcasts of presentations via Stoke's website. 5. Stoke's proprietary TANGO approach shows potential across several diseases.
The ongoing Phase 3 study for zorevunersen could lead to positive outcomes and future revenue, similar to past successful biotech product launches that significantly boosted stock value.
The announcement directly relates to the company’s lead drug and future presentations could sway investor sentiment, thus significantly influencing stock performance.
With zorevunersen in Phase 3, successful results can drive future growth. Historical trends show patient enrollment and results in key trials often lead to substantial stock price increases over one to two years.
Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the following upcoming investor conferences:
Cantor Global Healthcare Conference
Date: Thursday, September 4, 2025
Time: 3:20 p.m. ET
Morgan Stanley 23rd Annual Global Healthcare Conference
Date: Tuesday, September 9, 2025
Time: 1:05 p.m. ET
Live webcasts of each event, along with archived replays, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/.
About Stoke Therapeutics
Stoke Therapeutics (NASDAQ:STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250828755977/en/
Stoke Media & Investor Contacts:
Dawn Kalmar
Chief Communications Officer
dkalmar@stoketherapeutics.com
781-303-8302
Doug Snow
Director, Communications & Investor Relations
IR@stoketherapeutics.com
508-642-6485